Evidence map›Paper›PMID 41195388›Full record

ArticleFrontiers in microbiology2025

Determining the minimum inhibitory concentrations of pyrazinamide against

Maria Tamblin, Wanliang Shi, Liang Chen, Jessica Reynolds

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maria TamblinDepartment of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, United States.
Wanliang ShiPZA Innovation LLC, Baltimore, MD, United States.
Liang ChenDivision of Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, United States.
Jessica ReynoldsDepartment of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, United States.

Funding

Development of a Rapid Phenotypic Pyrazinamide Susceptibility Testing for Mycobacterium tuberculosis Using Well-Standardized ProtocolR44AI181252 · NIAID · PZA INNOVATION LLC · PI SHI, WANLIANG · 2024 to 2025
$1.7M
NIAID NIH HHS R44 AI181252
6 · The paper itself

Abstract

Introduction: Pyrazinamide (PZA) is a critical component of first-line tuberculosis (TB) treatment. Misdiagnosis of PZA resistance can lead to serious consequences, highlighting the need for accurate and reliable PZA susceptibility testing. While broth microdilution is a cost-effective and widely used method for determining the minimum inhibitory concentrations (MICs) of antibiotics, its current application for PZA has been limited by the requirement for acidic conditions in conventional Methods: In this study, we determined the MICs of PZA against the clinical isolates of pyrazinamidase-positive Results: The results showed that PZA MICs could be reliably determined in Discussion: This approach overcomes the limitations of existing acidic pH-based PZA susceptibility tests and provides a reliable, accurate, cost-effective method for detecting improved PZA resistance. Implementing this method could significantly enhance TB treatment, resistance surveillance, and efforts to combat drug-resistant TB.

Indexed as

broth microdilution methodminimum inhibitory concentrationMycobacterium tuberculosisphenotypicpyrazinamidesusceptibility

Identifiers

PMID41195388
PMCPMC12584017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.